GPC3 and hepatocellular carcinoma: We then administered 5 × 106 anti‐GPC3 CAR‐T (9F2) cells via portal vein injection on Day 7 post‐operation to mimic the treatment of small tumours representing early‐stage HCC and meanwhile, performed tail vein injection as a control for systemic delivery (Figure 2A).